Current Oncology Reports最新文献_第8页

Defining The Role for Hormone Therapy in Biochemically Recurrent Prostate Cancer: What Counts as a Win for Patients? 确定激素疗法在生化复发性前列腺癌中的作用：怎样才能让患者获胜？

IF 4.7 2区医学

Current Oncology Reports Pub Date : 2025-03-01 Epub Date: 2025-02-22 DOI: 10.1007/s11912-025-01647-5

Lauren O'Loughlin, Melissa L Abel, Ravi A Madan, David J Einstein

{"title":"Defining The Role for Hormone Therapy in Biochemically Recurrent Prostate Cancer: What Counts as a Win for Patients?","authors":"Lauren O'Loughlin, Melissa L Abel, Ravi A Madan, David J Einstein","doi":"10.1007/s11912-025-01647-5","DOIUrl":"10.1007/s11912-025-01647-5","url":null,"abstract":"Purpose of review: We evaluate unique clinical and drug development challenges in biochemically recurrent (BCR) prostate cancer. We examine risk stratification, critically appraise trials, and outline ongoing and future development of hormonal and non-hormonal options. We provide guidance for patient communication and examine how trial design may or may not reflect patient values.Recent findings: EMBARK established a potential role for enzalutamide with or without androgen deprivation therapy for certain patients with BCR, but questions remain about the study design and optimal usage. BCR is a heterogeneous condition with generally favorable long-term outcomes. Hormonal therapies are highly effective in suppressing-but not curing-micrometastatic disease, and are also highly effective when reserved for macrometastases, following surveillance. Ongoing studies are examining whether hormonal therapies add to metastasis-directed therapies and whether non-hormonal therapies may offer alternatives or combinations. Careful attention to trial design and endpoints will be essential for accurately measuring benefits and trade-offs.","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":" ","pages":"247-257"},"PeriodicalIF":4.7,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143476320","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advancements in the Diagnosis, Treatment, and Risk Stratification of Non-Muscle Invasive Bladder Cancer. 非肌肉浸润性膀胱癌的诊断、治疗和风险分层研究进展。

IF 4.7 2区医学

Current Oncology Reports Pub Date : 2025-03-01 Epub Date: 2025-02-20 DOI: 10.1007/s11912-025-01645-7

Shayan Smani, Julien DuBois, Kai Zhao, Ryan Sutherland, Syed N Rahman, Peter Humphrey, David Hesse, Wei Shen Tan, Darryl Martin, Soum D Lokeshwar, Fady Ghali

{"title":"Advancements in the Diagnosis, Treatment, and Risk Stratification of Non-Muscle Invasive Bladder Cancer.","authors":"Shayan Smani, Julien DuBois, Kai Zhao, Ryan Sutherland, Syed N Rahman, Peter Humphrey, David Hesse, Wei Shen Tan, Darryl Martin, Soum D Lokeshwar, Fady Ghali","doi":"10.1007/s11912-025-01645-7","DOIUrl":"10.1007/s11912-025-01645-7","url":null,"abstract":"Purpose of review: This review examines the evolving landscape of non-muscle invasive bladder cancer (NMIBC) management, focusing on risk stratification, novel therapeutic strategies, and the integration of biomarkers into clinical care.Recent findings: Emerging genomic markers such as FGFR3 and TERT promoter mutations show promise for diagnosis and personalized treatment. Advances in immunotherapy, including the use of pembrolizumab and nadofaragene firadenovec, offer options for BCG-unresponsive NMIBC, though challenges like cost and adverse effects remain. Current guidelines emphasize stratified care based on risk, balancing treatment intensity with recurrence and progression risks. While transurethral resection with intravesical therapy remains the standard for most NMIBC, early radical cystectomy is pivotal for select high-risk cases. Future directions highlight the need for biomarker-driven models to refine treatment paradigms, reduce overtreatment, and improve long-term outcomes. Continued clinical trials are essential to validate these approaches and address unmet needs in NMIBC care.","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":" ","pages":"236-246"},"PeriodicalIF":4.7,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143457155","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Weight Management for Fertility-Preservation Therapy in Endometrial Cancer: Opportunities and Challenges. 子宫内膜癌保生育治疗的体重管理：机遇与挑战。

IF 4.7 2区医学

Current Oncology Reports Pub Date : 2025-03-01 Epub Date: 2025-02-06 DOI: 10.1007/s11912-025-01635-9

XiaoDan Li, YiQian Chen, XiaoWei Li, Xiao Yang, Ling Zhou, Yuan Cheng, HongYi Hou, Dandan Yang, Yuanyuan Gong, Haihua Xiao, Jianliu Wang

{"title":"Weight Management for Fertility-Preservation Therapy in Endometrial Cancer: Opportunities and Challenges.","authors":"XiaoDan Li, YiQian Chen, XiaoWei Li, Xiao Yang, Ling Zhou, Yuan Cheng, HongYi Hou, Dandan Yang, Yuanyuan Gong, Haihua Xiao, Jianliu Wang","doi":"10.1007/s11912-025-01635-9","DOIUrl":"10.1007/s11912-025-01635-9","url":null,"abstract":"Purpose of review: Obesity is increasingly recognized as a significant factor impacting the outcomes of fertility-preserving therapies for endometrial cancer (EC). This review explores the effects of glycolipid metabolism on EC and its relationship with body weight. We will examine how excess body weight influences the effectiveness of fertility-preserving treatments and discuss potential mechanisms for effective weight management. Additionally, the review highlights the importance of comprehensive weight management as an adjunct strategy to enhance the efficacy of fertility-preserving interventions, providing insights into how to integrate metabolic health into clinical treatment protocols.Recent findings: Weight management can modify the tumor microenvironment by depriving the tumor of nutrients, whereas exercise can enhance immunity, potentially leading to tumor cell death. In addition, progesterone therapy may impede the proliferation of EC cells. Comprehensive weight management can serve as an essential adjuvant treatment for patients undergoing fertility-preserving therapies for EC. In this review, we highlight that comprehensive weight management can serve as a crucial adjuvant treatment for patients undergoing fertility-preserving therapies for endometrial cancer. Targeting glycolipid metabolism and addressing adiposity can improve hormonal balance, reduce inflammation, and enhance fertility outcomes. Further research is necessary to establish specific protocols and evaluate the effectiveness of these strategies in clinical practice.","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":" ","pages":"195-210"},"PeriodicalIF":4.7,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143254927","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cell-free Tumor DNA: a Promising Technology for Diagnosis, Surveillance and Therapeutic Decision in Urothelial Carcinoma of the Bladder. 无细胞肿瘤DNA：一种有前途的诊断、监测和治疗决策技术。

IF 4.7 2区医学

Current Oncology Reports Pub Date : 2025-03-01 Epub Date: 2025-02-12 DOI: 10.1007/s11912-025-01648-4

Lucas Motta Martinez, Lorena Cristina São Leão Ribeiro, Rodrigo Gilles Guidi, Caio Mazzonetto Teofilo de Moraes, Catharina Ribeiro Lyra, Bruno Liebl, Vinicius Henrique Almeida Guimarães, Richard Dobrucki de Lima, Lucas Schenk de Almeida, Caio Vinicius Suartz, William Carlos Nahas, Leopoldo Alves Ribeiro-Filho

引用次数: 0

Advances in Nasopharyngeal Carcinoma Staging: from the 7th to the 9th Edition of the TNM System and Future Outlook. 鼻咽癌分期的进展：从第7版到第9版TNM系统和未来展望。

IF 4.7 2区医学

Current Oncology Reports Pub Date : 2025-03-01 Epub Date: 2025-02-25 DOI: 10.1007/s11912-025-01651-9

Binhao Wu, Xiaozhong Chen, Caineng Cao

{"title":"Advances in Nasopharyngeal Carcinoma Staging: from the 7th to the 9th Edition of the TNM System and Future Outlook.","authors":"Binhao Wu, Xiaozhong Chen, Caineng Cao","doi":"10.1007/s11912-025-01651-9","DOIUrl":"10.1007/s11912-025-01651-9","url":null,"abstract":"Purpose of review: Nasopharyngeal carcinoma (NPC), characterized by its aggressive nature and sensitivity to radiation, demands accurate staging for optimal clinical outcomes. The purpose of this review was to provides a comprehensive overview of the evolution of the TNM staging system for NPC based on recent and previously published studies, with particular emphasis on the transition from the 7th to the 9th edition.Recent findings: The 9th edition introduces critical changes, particularly in the N and M classifications, to enhance prognostic accuracy. Our analysis also incorporates the burgeoning roles of biomarkers, especially Epstein-Barr virus (EBV)-DNA, and the potential of Artificial Intelligence (AI) in refining NPC staging. Each iteration of the TNM staging system for NPC has successfully enhanced the prognostic precision of NPC, with notable advancements from the 7th to the 9th edition. We also delves into the incorporation of biomarkers, such as EBV-DNA, and the potential of AI in refining staging accuracy. These innovations are anticipated to offer personalized prognoses and inform tailored treatment strategies for NPC patients in the future.","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":" ","pages":"322-332"},"PeriodicalIF":4.7,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143491139","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cardiotoxic Effects Following CAR-T Cell Therapy: A Literature Review. CAR-T细胞治疗后的心脏毒性作用：文献综述。

IF 4.7 2区医学

Current Oncology Reports Pub Date : 2025-02-01 Epub Date: 2025-01-21 DOI: 10.1007/s11912-024-01634-2

Tony Joseph, Jimmy Sanchez, Ahmed Abbasi, Lili Zhang, R Alejandro Sica, Tim Q Duong

{"title":"Cardiotoxic Effects Following CAR-T Cell Therapy: A Literature Review.","authors":"Tony Joseph, Jimmy Sanchez, Ahmed Abbasi, Lili Zhang, R Alejandro Sica, Tim Q Duong","doi":"10.1007/s11912-024-01634-2","DOIUrl":"10.1007/s11912-024-01634-2","url":null,"abstract":"Purpose of review: This paper reviewed the current literature on incidence, clinical manifestations, and risk factors of Chimeric Antigen Receptor T-cell (CAR-T) cardiotoxicity.Recent findings: CAR-T therapy has emerged as a groundbreaking treatment for hematological malignancies since FDA approval in 2017. CAR-T therapy is however associated with a few side effects, among which cardiotoxicity is of significant concern. There were only a few studies on CAR-T cardiotoxicity published to date with limited sample sizes, and their findings were heterogeneous. It was difficult to reach generalizable conclusions. CAR-T therapy was associated with significant risks for acute and subacute cardiotoxicity, as measured by echocardiograms, EKG, and blood biomarkers. Patients with cytokine release syndrome (CRS) grade 2 or higher were more likely to exhibit cardiotoxicity. The most prevalent cardiac events included hypotension-requiring inotropic or vasopressor support, tachycardia, heart failure/decompensation, atrial fibrillation, new or worsening cardiomyopathy, arrhythmia, myocarditis, cardiac arrest, and cardiovascular death. The most prevalent echocardiographic changes were systolic dysfunction and diastolic dysfunction, and abnormal echocardiogram findings. There were differences in findings between adult and pediatric patients. The long-term effects beyond a year post treatment remain largely unknown and long-term follow-up studies are warranted.","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":" ","pages":"135-147"},"PeriodicalIF":4.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11861112/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143001570","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Novel Surgical Initiatives in Gastroenteropancreatic Neuroendocrine Tumours. 胃肠胰神经内分泌肿瘤的新手术创举。

IF 4.7 2区医学

Current Oncology Reports Pub Date : 2025-02-01 Epub Date: 2025-01-25 DOI: 10.1007/s11912-024-01632-4

Alina S Ritter, Jelte Poppinga, Kira C Steinkraus, Thilo Hackert, Anna Nießen

{"title":"Novel Surgical Initiatives in Gastroenteropancreatic Neuroendocrine Tumours.","authors":"Alina S Ritter, Jelte Poppinga, Kira C Steinkraus, Thilo Hackert, Anna Nießen","doi":"10.1007/s11912-024-01632-4","DOIUrl":"10.1007/s11912-024-01632-4","url":null,"abstract":"Purpose of review: Neuroendocrine tumours (NET) are rare entities arising from hormone producing cells in the gastroentero-pancreatic (GEP) tract. Surgery is the most common treatment of GEP-NETs.Recent findings: Improvements in surgical techniques allow for more locally advanced and metastasised GEP-NETs to be resected. Laparoscopic and robotically--assisted approaches are increasingly being utilised in the resection of selected GEP-NETs and are facilitated by novel intraoperative tumour localisation tools and parenchyma-sparing methods. At the same time, some authors suggest that indications for formal resections of small well differentiated non-functioning pancreatic NETs and appendiceal NETs should be more restrictive. Advancements in surgery allows for tissue-sparing resections of GEP-NETs. Indications for surgical resection and the extent of the procedure are highly dependent on GEP-NET size, localisation and grading. Robotically assisted surgeries with intraoperative ultrasound and visualisation methods as well as vessel-sparing radical retrograde lymphadenectomies for small intestinal NETs seem to be the future of GEP-NET surgery.","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":" ","pages":"157-167"},"PeriodicalIF":4.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11861007/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143037404","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advances in Radiation Oncology in Soft Tissue Sarcoma. 软组织肉瘤放射肿瘤学研究进展

IF 4.7 2区医学

Current Oncology Reports Pub Date : 2025-02-01 Epub Date: 2025-01-21 DOI: 10.1007/s11912-025-01637-7

Sara B Leier, Safia K Ahmed

引用次数: 0

Evolving Strategies in the Management of Microsatellite Instability-High/Mismatch Repair Deficient Esophagogastric Adenocarcinoma. 微卫星不稳定性-高/错配修复缺陷食管胃腺癌的治疗策略的演变。

IF 4.7 2区医学

Current Oncology Reports Pub Date : 2025-02-01 Epub Date: 2025-01-03 DOI: 10.1007/s11912-024-01624-4

Nicole Baranda Balmaceda, Sunnie S Kim

引用次数: 0

NRG1 Fusions: The New Kid on the Block. NRG1 fusion: New Kid on The Block。